

La préservation d'organes dans le cancer du rectum : Pour qui ? Comment ?



Journée scientifique
Réseau Régional de Cancérologie Digestive
29/11/2024

Dr Ludovic EVESQUE – Centre Antoine Lacassagne – Nice
Dr Jérôme DURAND-LABRUNIE – Gustave Roussy – Villejuif



Comment ?

Préservation programmée



Préservation opportuniste

Préservation programmée : pour qui ?




Dr Angelita Habr-Gama

GRECCAR 2 trial



Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial

Eric Rullier, Véronique Vendrely, Julien Asselineau, Philippe Rouanet, Jean-Jacques Tuech, Alain Valverde, Cecile de Chaisemartin, Michel Rivoire, Bertrand Trilling, Mehrdad Jafari, Guillaume Portier, Bernard Meunier, Igor Sielezniew, Martin Bertrand, Frédéric Marchal, Anne Dubois, Marc Pocard, Anne Rullier, Denis Smith, Nora Frulio, Eric Frison, Quentin Denost



- At 5 years :
- Local Recurrence = 7%
 - 70% Salvage Surgery (100% R0)
 - 30% Chemo for M+
 - Disease Free Survival = 70%
 - Metastatic Disease = 18%
 - ypT0-1 = 10%
 - ypT2-3 = 30%
 - Overall Survival = 85%


TAU-TEM trial

N=173 patients
T2T3 N0M0 < 4 cm

ORIGINAL ARTICLE



Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study)[☆]

X. Serra-Aracil^{1*}, C. Pericay², J. Badia-Closa¹, T. Golda³, S. Biondo³, P. Hernández⁴, E. Targarona⁴, N. Borda-Arrizabalaga⁵, A. Reina⁶, S. Delgado⁷, F. Vallribera⁸, A. Caro⁹, J. Gallego-Plazas¹⁰, M. Pascual¹¹, C. Álvarez-Laso¹², H. G. Guadalajara-Labajo¹³ & L. Mora-Lopez¹



Awaiting long term & function/QoL results

Préservation programmée : comment ?



Contact Xray Brachytherapy









30mm applicator (FSD= 38mm)
covering the tumour with 5mm margin around it
Applied Dose at rectal mucosa surface 100% (30Gy)

Rectal mucosa
MM
MP
S



Rectal wall thickness 5mm
DD(5mm) 60% (18Gy)
DD(10mm) 38%(11.4Gy)




OPERA trial

N=141 patients
 T2T3 < 5 cm
 NON1 (0-3 gg < 8 mm)

Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial



Jean-Pierre Gerard, Nicolas Barbet, Renaud Schiappa, Nicolas Magné, Isabelle Martel, Laurent Mineur, Mélanie Deberne, Thomas Zilli, Amandeep Dhadda, Arthur Sun Myint, on behalf of the ICONe group



OPERA trial



Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial

Jean-Pierre Gerard, Nicolas Barbet, Renaud Schiappa, Nicolas Magné, Isabelle Martel, Laurent Mineur, Mélanie Deberne, Thomas Zilli, Amandeep Dhadha, Arthur Sun Myint, on behalf of the ICON6 group




- At 5 years :
- Local Recurrence = 16 vs 33 % (p=0.02)
 - Metastatic Disease = 14 %

HDR endorectal brachytherapy



MORPHEUS trial

T2T3 < 5 cm N0



	Number at Risk							
EBRT	20	17	10	5	3	1	1	
Brachytherapy	20	19	17	14	11	9	8	


Abbreviations: CI: Confidence Interval, HR-Hazard Ratio

*Vertical lines correspond to time of administrative censoring of patients

Article

MORPHEUS Phase II–III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results

Aurelie Garant ¹, Carol-Ann Vasilevsky ², Marylise Boutros ², Farzin Khosrow-Khavar ³, Petr Kavan ³, Hugo Diec ⁴, Sylvain Des Groseilliers ⁴, Julio Faria ², Emery Ferland ⁵, Vincent Pelsser ⁶, André-Guy Martin ⁷, Slobodan Devic ⁸ and Te Vuong ^{9,*}



GRECCAR 12 trial

3-7 May 2024

Glasgow, UK

ESTRO
2024

N=218 patients
T2T3 < 4 cm
N0N1 (0-3 gg <8 mm)




At 1 year :

- **ypT0 : 54 vs 37 % OR 2,19 [1,19;4,02]**
- **OP : 72 vs 63 % HR 1,88 [0,99;3,57]**

TRESOR trial

N=212 patients
T2N1 or T3N0N1
3 to 6 cm



At 3 year :

- Hypothesis : combining CXB with TNT will increase 3y SOP from 45% to 65%
- 12 Centers in France

Conclusion

Préservation programmée :

- Pour qui ? ADK bas/moyen rectum T2T3 N0-1 (gg<8mm) < 4 cm
- Comment ? Chimioradiothérapie +/- Radiothérapie de contact